Imagenetix Inc. Signs San Diego Padres Slugger Tony Gwynn and Wife Alicia as Spokespersons.

Business Editors & Health/Sports Writers

SAN DIEGO--(BUSINESS WIRE)--June 13, 2001

San Diego-based Imagenetix Inc. (OTCBB:IAGX), www.imagenetix.net, today announced that eight-time Major League batting champion and right fielder for the San Diego Padres, Tony Gwynn, and wife

Under the terms of the agreement, they will represent both Imagenetix and its Celadrin(TM) products, which are developed and privately labeled by the company.

In his 20 plus years with the San Diego Padres, Gwynn, 41, has undergone multiple knee surgeries. In addition, he has had to overcome pain from bone-on-bone grinding in the knee (from lack of cartilage) and the loss of mobility resulting from multiple injuries, surgeries, and the natural aging process. Since rehabilitation following his last surgery, Gwynn has been on a program of exercise and training.

To provide support for healthy joint function and mobility, Gwynn consumes daily doses of Celadrin(TM) capsules, a natural supplement that is a combination of fatty acid esters. He also topically rubs on Celadrin(TM) cream.

"We feel very fortunate to have put Tony on our Celadrin(TM) products," commented Bill Spencer, president of Imagenetix. "It has been very gratifying to see Tony rely successfully on Celadrin(TM) for joint support."

Said Gwynn: "I feel good. Everyone else is shocked by how well I am running. This is the best my knees have felt in probably five years."

Alicia Gwynn, a power walker, said, "Celadrin(TM) has made a huge difference to both Tony and me."

As a result of their positive experiences with the products, the Gwynns have joined the Imagenetix team as official spokespersons for the company and the Celadrin(TM) products. As compensation, they will receive a cash fee as well as stock options in Imagenetix.

Celadrin(TM) is a new nutritional supplement which can be sold through mass retailers, health and nutrition stores, network marketing companies and other distribution channels. As a nutritional supplement, neither FDA testing or approval is required for sale or purchase of the products. However, Imagenetix chose to subject Celadrin(TM) to a recent clinical study.

On Dec. 13, 2000, the company announced results of its double-blind, multi-center, placebo-controlled trial of Celadrin(TM) (during the trial the product was known as CMC or CM Complex). In the trial, Imagenetix examined the impact that a 60-day oral administration of Celadrin(TM) had on 93 patients. The patients ranged in age from 37 to 77 years. Half the patients received Celadrin(TM), and the remainder received a placebo.

Data indicated that Celadrin(TM) is statistically significant in increasing joint flexibility, improving flat ground walking and traversing up and down stairs.

"I have been involved in oral studies of products for a long time," said Dr. M. Nagendran, a medical doctor who conducted the Imagenetix study in India in Fall 2000. "This study shows that Celadrin(TM) provides long-lasting benefits; I think it is one of the better products on the market."

Celadrin(TM) is competing for market share with glucosamine, a natural product with annual sales of approximately $1.7 billion.

The study, which received Institutional Review Board approval from the Medical Center in Bangalore, India, showed that Celadrin(TM) exhibited no known side effects. A presentation of the clinical study was made at the Experimental Biology Conference in Orlando, Fla. in April of 2001.

About Tony Gwynn

Gwynn, age 41, is an eight-time Major League batting champ. He plays right field and is in his 20th season with the only team he has played for professionally, the San Diego Padres. Tony has recently come back from his sixth knee surgery.

After having positive experiences with the Celadrin(TM) products, both Tony and his wife Alicia have become spokespersons for Imagenetix and the Celadrin(TM) products. Under the terms of the agreement, Tony and Alicia will be spokespersons for a 2-year period and will receive cash and stock options in Imagenetix.

About Imagenetix Inc.

San Diego-based Imagenetix (www.imagenetix.net), is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to address specific health issues on a global basis. Imagenetix has quickly emerged as a force in the rapidly growing nutritional and skin care products industries.

The company develops, formulates and privately labels proprietary and leading-edge products to be marketed globally through multiple channels of distribution and currently privately labels more than 60 formulations of innovative products. Unlike many competitors in the natural-based product industry, Imagenetix not only researches the latest scientific findings, but also often conducts scientific tests while developing its proprietary products.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.